Trans Sodium Crocetinate

Glioma

Diffusion Pharmaceuticals IncPhase 1/2Dormant

D

31/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 17/ 100
Competitive Position: 73/ 100

Competitive context

96 Active assets in the Glioma cohort.

Asset / Sponsor	Phase	Rating
Olutasidenib Rigel Pharmaceuticals	Phase 4	BBB
Irinotecan Kailin Yang, MD, PhD	Phase 3	B
Valproic Acid Medical University of South Carolina	Phase 2	B
DIANHYDROGALACTITOL Kintara Therapeutics, Inc.	Phase 2	B
Cyclophosphamide Essen Biotech	Phase 2	B

View all 50 →

Same molecule, other indications

Trans Sodium Crocetinate is also rated in:

glioblastomaDormant

C

Indicative ·

38 / 100

stroke disorderDormant

C

Indicative ·

33 / 100

malignant gliomaDormant

D

Indicative ·

27 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.